PT  - JOURNAL ARTICLE
AU  - Butterman, Eric
ED  - Steenbergen, Judith
TI  - CXA-201 Effective against Common ICU Pathogens, Including MDR Gram-Negative Pathogens and Pseudomonas aeruginosa
DP  - 2011 Dec 01
TA  - MD Conference Express
PG  - 10--11
VI  - 11
IP  - 12
4099  - http://mdc.sagepub.com/content/11/12/10.short
4100  - http://mdc.sagepub.com/content/11/12/10.full
AB  - Using a pharmacokinetic/pharmacodynamic (PK/PD) target algorithm, the in vitro potency of CXA-201 (CXA101/tazobactam), a novel cephalosporin and b-lactamase inhibitor combination that is being developed to treat serious bacterial infections, was reported to be lower in isolates from the intensive care unit (ICU) compared with non-ICU isolates.